In recent FDA Phase 2 trials, a single dose of the experimental psychedelic luvesilocin eliminated postpartum depression symptoms in 71% of patients within seven days. The breakthrough medication will enter Phase 3 trials by late 2026.

In the Phase 2 study, 77% of postpartum women who received a psychedelic dose, 30mg of luvesilocin, had significant improvement in their postpartum depression. Overall, 71% had no symptoms of postpartum depression seven days after the psychedelic session.

  • SailorFuzzEnglish
    3·
    17 days ago

    It’s literally a plot in “Common Side Effects”.

    There exists a mushroom that can magically and fully cure people… but instead of that, can big pharma synthesize a controlled approximate that doesn’t cure people but does exceeds competitors. Thereby ensuring repeat customers and profiting by withholding the real cure.